MIST — Milestone Pharmaceuticals Share News
0.000.00%
Last trade - 00:00- $80.70m
- $51.06m
- $1.55m
Milestone Pharmaceuticals Inc expected to post a loss of 39 cents a share - Earnings Preview
Brief: Milestone Pharmaceuticals Announces Publication Of Results From Phase 3 RAPID Clinical Trial Of Etripamil Nasal Spray In Patients With PSVT In The Lancet
Brief: Milestone Pharmaceuticals Announces Publication Of Results From Phase 3 RAPID Clinical Trial Of Etripamil Nasal Spray In Patients With PSVT In The Lancet
Milestone Pharmaceuticals Inc reports results for the quarter ended in March - Earnings Summary
Brief: Milestone Pharmaceuticals Reports Q1 2023 Financial Results, Provides Clinical And Corporate Update
Milestone Pharmaceuticals Inc expected to post a loss of 40 cents a share - Earnings Preview
Brief: Milestone Pharmaceuticals Posts Q4 Loss Per Share $0.31
Milestone Pharmaceuticals Inc reports results for the quarter ended in December - Earnings Summary
Milestone Pharma gains on $125 million funding agreement
Brief: Milestone Pharmaceuticals Announces $125 Million Strategic Financing With RTW Investments To Support The Advancement Of Etripamil For PSVT
Milestone Pharmaceuticals Inc expected to post a loss of 33 cents a share - Earnings Preview
Brief: Milestone Pharma Progresses Clinical & Regulatory Activities For Etripamil
Milestone Pharmaceuticals Inc reports results for the quarter ended in September - Earnings Summary
Brief: Milestone Pharmaceuticals Reports Third Quarter Financial Results
Brief: Milestone Pharmaceuticals Reports Q3 Loss Of $0.34 Per Share
Milestone Pharmaceuticals Inc expected to post a loss of 41 cents a share - Earnings Preview
Brief: Milestone Pharma Announces Presentation Of Data From Phase 3 RAPID Clinical Trial Of Etripamil Nasal Spray At The American Heart Association Scientific Sessions 2022
U.S. STOCKS ON THE MOVE-Alvotech, Verizon, Lyft, BofA
U.S. STOCKS ON THE MOVE-Gold miners, Protera, Sorrento